Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

ose in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... MN (PRWEB) March 26, 2015 Agnition ... upcoming episode of American Farmer, airing for the first ... The segment of American Farmer will explore the extremely ... provides crop producers with a patented Microbial Catalystâ„¢ technology ... and greater yields. The segment will air again on ...
(Date:3/25/2015)... Md. , March 25, 2015 Optimal ... the Vaccine Industry Excellence (ViE) Award "Best Clinical Site ... consecutive year that Optimal has been selected as a ... Vaccine Congress, receiving a "Highly Recommended" distinction in 2014. ... recognition of the efforts, accomplishments, and positive contributions of ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
(Date:3/25/2015)... 2015 Accelovance, a therapeutically focused contract research ... Contract Research Organization" at the upcoming Vaccine Industry Excellence ... This is the eighth consecutive year Accelovance ... winning for "Best Contract Research Organization" in 2009, 2010, ... 2013. "We,re excited to be a finalist ...
Breaking Biology Technology:Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2
... MEETING, Pa., Dec. 1 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... today announced,that the company will attend the 20th Annual ... The 20th Annual Piper Jaffray Health Care ... Wednesday, December 3, 2008, at the New York,Palace Hotel ...
... /PRNewswire-Asia/ -- China Medicine Corporation,(OTC Bulletin Board: ... leading,developer and distributor of prescription and over ... and dietary supplements, and,medical devices and medical ... GSP (Good Supply Practice for Pharmaceutical Products) ...
... /PRNewswire-Asia/ -- Tigermed Consulting Co., Ltd,a leading ... that it has,established a subsidiary, Hunan Tigermed ... University (CSU). The establishment of ... of a nationwide first-rate Phase,I Clinical Laboratory, ...
Cached Biology Technology:China Medicine Corporation Awarded GSP Certification 2China Medicine Corporation Awarded GSP Certification 3Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya) 2
(Date:3/12/2015)... March 12, 2015 WHEN:Tuesday, March 17, 2015 ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must ... in several different markets and industries. This is ... an uptrend. Join Frost & ...
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... A family of biodegradable polymers called polyketals and their ... acute lung injury, acute liver failure and inflammatory bowel ... acid to disease locations in the body. "The ... get the drugs inside the body to the diseased ...
... PhD, Associate Professor of Neuroscience at LSU Health Sciences ... only naturally occurring fatty acids in the brain ... originally identified as the targets of THC (the psychoactive ... from neurodegenerative diseases like Alzheimer,s and Parkinson,s. Published in ...
... issue of the Journal of Lipid Research suggests ... the rising rate of diabetes, especially in children and young ... mechanism of inheritance; kids get half their genes from mom ... understand additional kinds of inheritance like metabolic programming, which occurs ...
Cached Biology News:Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 3LSUHSC research reports new method to protect brain cells from diseases like Alzheimer's 2
...
... assay (ELISA) test kits are qualitative one-step ... detection of drugs and/or their metabolites in ... forensic use only. It is recommended that ... quantitative method such as GC/MS. The ...
96 Well Base Plate...
... Inhibitor is a recombinant human protein produced in ... neutral pancreatic RNase A type enzymes. The ... binds RNases in a 1:1 ratio. The enzyme ... many tissues and cell types. Addition of the ...
Biology Products: